There is increasing importance of differentiation in the pharmaceutical industry, especially given the political, regulatory, and financial challenges we face.
Jean-Marc Huet
CFO and Executive Vice President, Bristol-Myers Squibb
There is increasing importance of differentiation in the pharmaceutical industry, especially given the political, regulatory, and financial challenges we face. That's why BMS is executing a clear strategy to become a leading biopharma company while remaining focused on operational excellence and strengthening our balance sheet. What is needed now more than ever is the ability to turn challenges into opportunities; we're working to make sure BMS is well positioned to do so.
An innovative environment naturally creates leadership, and provides opportunities for successful, driven people. I make sure that the people whom I work with have what they need in order to be successful. We're all doers here, and that spirit will help us transform into the biopharma company we know we can be.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.